Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients - Wikidata - awgldk - TriplyDB

Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients

Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients

http://www.wikidata.org/entity/Q24651466

about

Toxicity of polymyxins: a systematic review of the evidence from old and recent studies A new strategy to fight antimicrobial resistance: the revival of old antibiotics Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients Toxicity after prolonged (more than four weeks) administration of intravenous colistin What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression Renal and neurological side effects of colistin in critically ill patients Colistin for lung infection: an update Antibacterial resistance worldwide: causes, challenges and responses Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections.Parenteral colistin for the treatment of severe infections: a single center experience.Successive emergence of Enterobacter aerogenes strains resistant to imipenem and colistin in a patient.Metallo-beta-lactamases: the quiet before the storm?Detection of colistin sensitivity in clinical isolates of Acinetobacter baumannii in Iran Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa.Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.A retrospective observational study on the efficacy of colistin by inhalation as compared to parenteral administration for the treatment of nosocomial pneumonia associated with multidrug-resistant Pseudomonas aeruginosa.Colistin dosing and nephrotoxicity in a large community teaching hospital.Occurrence of carbapenem-resistant Acinetobacter baumannii clones at multiple hospitals in London and Southeast England.Validation of a model to predict the risk of nephrotoxicity in patients receiving colistin The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature.Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa.Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes.Acinetobacter baumannii: emergence of a successful pathogen Neurotoxic effects associated with antibiotic use: management considerations The use of intravenous colistin among children in the United States: results from a multicenter, case series High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study.Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options.Effect of systemic infection induced by Pseudomonas aeruginosa on the brain uptake of colistin in mice.Treatment options for multidrug-resistant bacteria.Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit.Multidrug-resistant organisms in military wounds from Iraq and Afghanistan.Nephrotoxicity and efficacy assessment of polymyxin use in 92 transplant patients Population pharmacokinetic analysis of colistin in burn patients.Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa Polymyxin B: similarities to and differences from colistin (polymyxin E).Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults.Utilization of colistin for treatment of multidrug-resistant Pseudomonas aeruginosa

P2860

Q21092897-5B850C8A-447C-4856-A116-5A3ACCCC98F0 Q21131083-8CDC82BA-0113-4950-9AF5-EA31BB7565F8 Q24673399-DF81FBF3-5953-430C-B762-44BEC19AF28E Q24798835-1AFC6C9D-84B7-4C6C-AF71-1657D1E7D2C7 Q26999921-B2B76382-CF17-4884-A4E8-CE174DEDB699 Q27499294-A2F805B9-C82C-430B-A500-BC7FC8411059 Q28082041-00A244F1-623D-4D0A-9875-AE270F973939 Q29620008-271ADB94-6756-472E-AF02-AA45534BC50D Q33416170-821AE78D-78DA-47BA-885E-69B87459A32C Q33653353-4AC20791-CF65-487A-AFAE-D1C1E08A7FB7 Q33721943-3F943F3B-D647-4888-95F3-8D898508D7EE Q33755227-8CA20D57-F909-466E-9E56-7FB961EF8645 Q33833251-72BE2572-1818-4C97-A700-C18A0C0F9E7E Q33935368-24577C07-EB18-4F2E-8A2E-1C2AD11AE7AE Q33938143-04C2FE4E-6800-4B06-B67A-8023EFDCE54D Q34074975-8C13192C-720A-4A30-B1F3-1FA4CF662587 Q34150958-4B96920F-0479-4B00-A1FF-C10D26D71486 Q34571574-927E2455-7D45-4538-B207-540DBF95E2A8 Q34596336-59EE08A7-A77C-4D78-B1BC-145A78700425 Q34652418-DED1A3A9-EA3A-4737-907A-2584F98BC8B0 Q34680516-606E3BF7-38CD-403D-9E63-799B6E744A55 Q34686057-CA01ADE8-8AFA-4B66-955A-5B50F75806F8 Q34757004-48662BA1-C9A1-4908-BCD6-A948356DD0D6 Q34795807-106C3D2D-6B62-4251-844A-0E223B6EC821 Q35219637-C67786F8-464A-46E5-BEFF-191029136357 Q35592264-216F1BF3-3319-4766-ABA8-5DBE3B2E09FB Q35977417-29453B6B-6AE9-43AF-99C8-CC3CC361EBC5 Q36095874-D4858300-9870-4DE8-AA9B-D58845037564 Q36240813-AFA89EDC-04D4-428F-9C8A-CBE156A94F56 Q36268383-7BF43FA8-E841-48FC-9969-B8281C579A83 Q36276961-DB42D265-F4B1-45CB-9013-3469DE754546 Q36607401-42B7F1DE-4504-40AA-AF4D-74F11FC94407 Q36612595-41CE4B29-23C9-464C-829C-B30B456EC8FF Q36657841-E2A1F8B2-DBF1-459E-AA08-BE7F6982EB43 Q36667079-51C6B4ED-7F78-42AF-9AA7-67C82D5CB138 Q36785854-23148100-53A9-41E5-AB3D-062A61B32CAE Q36887819-0891D2D9-787E-43A6-9FF0-C3862010A20C Q36960059-B3950EA5-A0EB-457A-84F9-8B7D9BDCDF7E Q37029217-A132DFB1-6304-4A38-AB3D-42ED8E98BC25 Q37145741-9331E1EC-DF95-4E9E-B575-D5718C0613CF

P2860

Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients

http://www.wikidata.org/entity/Q24651466

description

2003 nî lūn-bûn

@nan

2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Intravenous colistin in the tr ...... lli in critically ill patients

@ast

Intravenous colistin in the tr ...... lli in critically ill patients

@en

Intravenous colistin in the tr ...... lli in critically ill patients

@nl

type

label

Intravenous colistin in the tr ...... lli in critically ill patients

@ast

Intravenous colistin in the tr ...... lli in critically ill patients

@en

Intravenous colistin in the tr ...... lli in critically ill patients

@nl

prefLabel

Intravenous colistin in the tr ...... lli in critically ill patients

@ast

Intravenous colistin in the tr ...... lli in critically ill patients

@en

Intravenous colistin in the tr ...... lli in critically ill patients

@nl

P1433

Q24651466-D662F189-9974-483C-BA5C-17F442FE3177

P1476

Q24651466-6BC05AF6-CACE-4A9E-A18A-F6041DC1A2D1

P2093

Q24651466-5D1DE090-FB24-452F-85B2-DE4BB68EBE52

Q24651466-9C41CEB6-2E91-4990-86E8-89C0495DF580

Q24651466-9D2FFF55-6E54-40F1-BE36-80C2E8DC81A6

Q24651466-9FDA6C72-1F18-4EDC-9B6F-F5AADB57EB18

Q24651466-A60DDC48-3D89-41CF-A2E1-C7E169052051

Q24651466-CAC9F62E-38B0-4F98-96ED-66A78BEBD26F

Q24651466-DFE01F38-74C8-4DBC-9F72-5C4665D0CDCA

P2860

Q24651466-02EB0FFE-426B-40A4-87E3-DE4F12FFA418

Q24651466-10F58CCA-86B8-410F-8A60-8A0C7445C5D9

Q24651466-12E35A99-22E0-4375-8A1E-DB37B011C7AF

Q24651466-2A776244-FE54-409B-84E3-3E520116B310

Q24651466-3FE2992A-732E-4C28-85D7-EB46BDCA7EA3

Q24651466-4DA4AD0F-0635-4DDA-BF97-F398B115529B

Q24651466-58A29D94-2A96-4907-B9A9-8AC01322633B

Q24651466-5E17C5CE-781E-44EE-965E-4076C5A1EEDB

Q24651466-654745BF-20F4-4B73-BB10-5CE14AB2F4C9

Q24651466-67C0D1E7-D07C-4730-9A84-D082054B9F6C

P2888

Q24651466-E6D6488B-5764-4387-82B0-40061138B269

P304

Q24651466-991FA132-2893-4C6D-954C-ABFA82A0071C

P31

Q24651466-9E2835A6-3602-49A4-8C0D-A11384E898B0

P356

Q24651466-39DED69E-F259-4B10-999A-26ADC037D8C2

P407

Q24651466-623952C6-A7C0-4F71-A37F-1B1B51EDA4B7

P433

Q24651466-80B00503-9D8E-499C-9A6A-65EF1FAB07F4

P478

Q24651466-5E7E8629-B2A5-4D1E-A996-9633819CA5A3

P577

Q24651466-321E0228-B761-4741-B1C5-82A692A1FEC3

P5875

Q24651466-DE6D4D2F-3842-4E9F-9183-92817806ABDE

P6179

Q24651466-C944AB60-D4E7-4956-AC6A-67A2A2338E03

P698

Q24651466-EAFAE4E3-92F5-4503-B379-ED3B1B808C5D

P921

Q24651466-2B57897F-9792-4ADD-8A3F-C4C534B0CC75

Q24651466-74A602C2-EEBB-4DDC-952C-8F592F4507EE

Q24651466-9CF6105C-841E-4CA3-9425-AE7C0C8A5C11

Q24651466-A609C34C-A3B6-49AC-A950-39D98915FB6E

Q24651466-C4170F75-87DE-4499-96F5-22CA6BD8B348

P932

Q24651466-097DE440-31CA-449F-B8C0-DD75108935DD

P356

P1433

P1476

Intravenous colistin in the tr ...... lli in critically ill patients

@en

P2093

Alexandra Koutsoukou

http://www.w3.org/2001/XMLSchema#string

Christiana Koumoudiou

http://www.w3.org/2001/XMLSchema#string

Haralampos Apostolakos

http://www.w3.org/2001/XMLSchema#string

Ioannis Alamanos

http://www.w3.org/2001/XMLSchema#string

Leonidas Gregorakos

http://www.w3.org/2001/XMLSchema#string

Maria Athanasiou

http://www.w3.org/2001/XMLSchema#string

Nikolaos Markou

http://www.w3.org/2001/XMLSchema#string

P2860

Peptide antibiotics.

Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria.

Safety and tolerability of bolus intravenous colistin in acute respiratory exacerbations in adults with cystic fibrosis.

Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines.

Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii.

In vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibiotics.

Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy.

Four years' experience of intravenous colomycin in an adult cystic fibrosis unit.

The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting.

The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection.

P2888

P304

R78-83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/CC2358

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2003-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10566758

http://www.w3.org/2001/XMLSchema#string

P6179

1047917257

http://www.w3.org/2001/XMLSchema#string

P698

12974973

http://www.w3.org/2001/XMLSchema#string

P921

Gram-negative bacteria

multiple drug resistance

P932

270720

http://www.w3.org/2001/XMLSchema#string